Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Martinez-Martin, P; Reddy, P; Katzenschlager, R; Antonini, A; Todorova, A; Odin, P; Henriksen, T; Martin, A; Calandrella, D; Rizos, A; Bryndum, N; Glad, A; Dafsari, HS; Timmermann, L; Ebersbach, G; Kramberger, MG; Samuel, M; Wenzel, K; Tomantschger, V; Storch, A; Reichmann, H; Pirtosek, Z; Trost, M; Svenningsson, P; Palhagen, S; Volkmann, J; Chaudhuri, KR.
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
Mov Disord. 2015; 30(4):510-516
Doi: 10.1002/mds.26067
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Wenzel Karoline
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Subcutaneous apomorphine infusion (Apo) and intrajejunal levodopa infusion (IJLI) are two treatment options for patients with advanced Parkinson's disease (PD) and refractory motor complications, with varying cost of treatment. There are no multicenter studies comparing the effects of the two strategies. This open-label, prospective, observational, 6-month, multicenter study compared 43 patients on Apo (48.8% males, age 62.3 ± 10.6 years; disease duration: 14 ± 4.4 years; median H & Y stage 3; interquartile range [IQR]: 3-4) and 44 on IJLI (56.8% males, age 62.7 ± 9.1 years; disease duration: 16.1 ± 6.7 years; median H & Y stage 4; IQR, 3-4). Cohen's effect sizes (≥0.8 considered as large) were "large" with both therapies with respect to total motor, nonmotor, and quality-of-life scores. The Non-Motor Symptoms Scale (NMSS) with Apo showed moderate improvement, whereas sleep/fatigue, gastrointestinal, urinary, and sexual dimensions of the NMSS showed significantly higher improvement with IJLI. Seventy-five percent on IJLI improved in their quality-of-life and nonmotor symptoms (NMS), whereas in the Apo group, a similar proportion improved in quality of life, but 40% in NMS. Adverse effects included peritonitis with IJLI and skin nodules on Apo. Based on this open-label, nonrandomized, comparative study, we report that, in advanced Parkinson's patients, both IJLI and Apo infusion therapy appear to provide a robust improvement in motor symptoms, motor complications, quality-of-life, and some NMS. Controlled, randomized studies are required. © 2014 International Parkinson and Movement Disorder Society.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Antiparkinson Agents - administration & dosage
- Apomorphine - administration & dosage
- Female -
- Humans -
- Infusions, Subcutaneous - methods
- Jejunum - drug effects
- Jejunum - physiology
- Levodopa - administration & dosage
- Male -
- Middle Aged -
- Parkinson Disease - drug therapy
- Parkinson Disease - physiopathology
- Prospective Studies -
- Severity of Illness Index -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Parkinson's disease
- nonmotor symptoms
- apomorphine infusion
- intrajejunal levodopa infusion
- quality of life